Diverse microtubule-targeted anticancer agents kill cells by inducing chromosome missegregation on multipolar spindles

Nuclear chromosome locations dictate segregation error frequencies

(2022) Sjoerd J. Klaasen et al.   NATURE

Consequences of chromosome gain: A new view on trisomy syndromes

(2022) Maria Krivega et al.   AMERICAN JOURNAL OF HUMAN GENETICS

Forcing dividing cancer cells to die; low‐dose drug combinations to prevent spindle pole clustering

(2021) Eloise Ducrey et al.   APOPTOSIS

Clonal selection of stable aneuploidies in progenitor cells drives high-prevalence tumorigenesis

(2021) Marianna Trakala et al.   GENES & DEVELOPMENT

Chromosomal instability sensitizes patient breast tumors to multipolar divisions induced by paclitaxel

(2021) Christina M. Scribano et al.   Science Translational Medicine

Systems approaches identify the consequences of monosomy in somatic human cells

(2021) Narendra Kumar Chunduri et al.   Nature Communications

Chromosome Missegregation as a Modulator of Radiation Sensitivity

(2021) Pippa F. Cosper et al.   SEMINARS IN RADIATION ONCOLOGY

p53 is not required for cell death and tumor suppression caused by high chromosomal instability

(2020) Laura C Funk et al.   MOLECULAR CANCER RESEARCH

The Cytoplasmic DNA Sensor cGAS Promotes Mitotic Cell Death

(2019) Christian Zierhut et al.   CELL

Chromosomal instability suppresses the growth of K-Ras-induced lung adenomas

(2019) Christopher D. Laucius et al.   CELL CYCLE

Context is everything: aneuploidy in cancer

(2019) Uri Ben-David et al.   NATURE REVIEWS GENETICS

Human chromosome‐specific aneuploidy is influenced by DNA ‐dependent centromeric features

(2019) Marie Dumont et al.   EMBO JOURNAL

Mps1 inhibitors synergise with low doses of taxanes in promoting tumour cell death by enhancement of errors in cell division

(2018) Ana Rita R. Maia et al.   BRITISH JOURNAL OF CANCER

Non-random Mis-segregation of Human Chromosomes

(2018) Joseph Thomas Worrall et al.   Cell Reports

The diverse consequences of aneuploidy

(2018) Narendra Kumar Chunduri et al.   NATURE CELL BIOLOGY

Fighting tubulin-targeting anticancer drug toxicity and resistance

(2017) Roberta Visconti et al.   ENDOCRINE-RELATED CANCER

p53 Prohibits Propagation of Chromosome Segregation Errors that Produce Structural Aneuploidies

(2017) Mar Soto et al.   Cell Reports

High rates of chromosome missegregation suppress tumor progression but do not inhibit tumor initiation

(2016) Lauren M. Zasadil et al.   MOLECULAR BIOLOGY OF THE CELL

Chromosomal Instability Affects the Tumorigenicity of Glioblastoma Tumor-Initiating Cells

(2016) K. M. Godek et al.   Cancer Discovery

Negative Selection and Chromosome Instability Induced by Mad2 Overexpression Delay Breast Cancer but Facilitate Oncogene-Independent Outgrowth

(2016) Konstantina Rowald et al.   Cell Reports

Selective advantage of trisomic human cells cultured in non-standard conditions

(2016) Samuel D. Rutledge et al.   Scientific Reports

Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model

(2015) A. R. R. Maia et al.   ANNALS OF ONCOLOGY

Dynamics of Tumor Heterogeneity Derived from Clonal Karyotypic Evolution

(2015) Ashley M. Laughney et al.   Cell Reports

Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer

(2014) Kristi McIntyre et al.   BREAST CANCER RESEARCH AND TREATMENT

Aneuploidy: implications for protein homeostasis and disease

(2014) A. B. Oromendia et al.   Disease Models & Mechanisms

Targeting Microtubules by Natural Agents for Cancer Therapy

(2014) E. Mukhtar et al.   MOLECULAR CANCER THERAPEUTICS

Oncogene-like induction of cellular invasion from centrosome amplification

(2014) Susana A. Godinho et al.   NATURE

Cytotoxicity of Paclitaxel in Breast Cancer Is due to Chromosome Missegregation on Multipolar Spindles

(2014) L. M. Zasadil et al.   Science Translational Medicine

Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer

(2013) Robert Jones et al.   INVESTIGATIONAL NEW DRUGS

Discovery of Allosteric Inhibitors of Kinesin Spindle Protein (KSP) for the Treatment of Taxane-Refractory Cancer: MK-0731 and Analogs

(2012) Christopher D. Cox et al.   Anti-Cancer Agents in Medicinal Chemistry

A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas – a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network

(2012) K Mross et al.   BRITISH JOURNAL OF CANCER

Inhibitors Targeting Mitosis: Tales of How Great Drugs against a Promising Target Were Brought Down by a Flawed Rationale

(2012) E. Komlodi-Pasztor et al.   CLINICAL CANCER RESEARCH

Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors

(2012) A. Cervantes et al.   CLINICAL CANCER RESEARCH

Aneuploidy as a mechanism for stress-induced liver adaptation

(2012) Andrew W. Duncan et al.   JOURNAL OF CLINICAL INVESTIGATION

First-time-in-human study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein E (CENP-E), in patients with refractory cancer

(2011) Vincent Chung et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Comparison of weekly versus every 3 weeks paclitaxel in the treatment of advanced solid tumors: A meta-analysis

(2011) Ta-Chen Huang et al.   CANCER TREATMENT REVIEWS

Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia

(2011) H. M. Kantarjian et al.   INVESTIGATIONAL NEW DRUGS

A phase I trial of MK-0731, a Kinesin Spindle Protein (KSP) inhibitor, in patients with solid tumors

(2011) Kyle Holen et al.   INVESTIGATIONAL NEW DRUGS

Mitosis is not a key target of microtubule agents in patient tumors

(2011) Edina Komlodi-Pasztor et al.   Nature Reviews Clinical Oncology

A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma

(2010) G. Gorgun et al.   BLOOD

Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma

(2010) Xiaojing Wang et al.   BRITISH JOURNAL OF HAEMATOLOGY

CLASP1, astrin and Kif2b form a molecular switch that regulates kinetochore-microtubule dynamics to promote mitotic progression and fidelity

(2010) Amity L Manning et al.   EMBO JOURNAL

Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)

(2010) Patrick Schöffski et al.   EUROPEAN JOURNAL OF CANCER

AURKA inhibitors: Right in time

(2010) Heinrich Kovar   PEDIATRIC BLOOD & CANCER

Antitumor activity of an allosteric inhibitor of centromere-associated protein-E

(2010) K. W. Wood et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Discovery of the First Potent and Selective Inhibitor of Centromere-Associated Protein E: GSK923295

(2010) Xiangping Qian et al.   ACS Medicinal Chemistry Letters

Eribulin Binds at Microtubule Ends to a Single Site on Tubulin To Suppress Dynamic Instability

(2009) Jennifer A. Smith et al.   BIOCHEMISTRY

Whole Chromosome Instability Caused by Bub1 Insufficiency Drives Tumorigenesis through Tumor Suppressor Gene Loss of Heterozygosity

(2009) Darren J. Baker et al.   CANCER CELL

Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

(2009) Linda T. Vahdat et al.   JOURNAL OF CLINICAL ONCOLOGY

Polo-Like Kinase (PLK) Inhibitors in Preclinical and Early Clinical Development in Oncology

(2009) P. Schoffski   ONCOLOGIST

Elevating the frequency of chromosome mis-segregation as a strategy to kill tumor cells

(2009) Aniek Janssen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Acquisition of Aneuploidy Provides Increased Fitness during the Evolution of Antifungal Drug Resistance

(2009) Anna M. Selmecki et al.   PLoS Genetics

A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer

(2008) G. Fountzilas et al.   BREAST CANCER RESEARCH AND TREATMENT

Cancer Cells Display Profound Intra- and Interline Variation following Prolonged Exposure to Antimitotic Drugs

(2008) Karen E. Gascoigne et al.   CANCER CELL

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Genome stability is ensured by temporal control of kinetochore–microtubule dynamics

(2008) Samuel F. Bakhoum et al.   NATURE CELL BIOLOGY